Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD

Last updated: February 27, 2020
Sponsor: Orion Corporation, Orion Pharma
Overall Status: Completed

Phase

N/A

Condition

Asthma

Treatment

N/A

Clinical Study ID

NCT03755544
3106013
  • Ages > 18
  • All Genders

Study Summary

A non-interventional study to assess the clinical effectiveness of Salmeterol/fluticasone Easyhaler to achieve and maintain asthma or COPD control.

Eligibility Criteria

Inclusion

Main Inclusion Criteria:

  1. Male or female patients with asthma or COPD who have been using salmeterol/fluticasonepropionate combination treatment for at least 3 months before the study

  2. Age ≥18 years.

  3. Written informed consent obtained.

Exclusion

Main Exclusion Criteria:

  1. Pregnant or lactating female patients.

  2. Participation in other clinical studies during the study.

  3. Known hypersensitivity (allergy) to salmeterol, fluticasone propionate or theexcipient lactose

  4. Any significant medical disease or condition or other factor that might interfere withstudy assessments or study participation.

Study Design

Total Participants: 231
Study Start date:
January 16, 2019
Estimated Completion Date:
February 13, 2020

Study Description

A prospective, open-label, non-interventional, multicentre study in adult patients with asthma or COPD who are treated with Salmeterol/fluticasone Easyhaler. During the study the Salmeterol/fluticasone Easyhaler will be used according to the Summary of Product Characteristics. Clinical effectiveness of the treatment will be evaluated with change in asthma or COPD symptoms during 12 weeks treatment.

Connect with a study center

  • Lungenpraxis

    Hamburg,
    Germany

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.